2026-08-05T16:12:46Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89932024-11-29T08:19:32Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Castilla Catalán, Jesús author Navascués, Ana author Casado, Itziar author Pérez-García, Alejandra author Aguinaga, Aitziber author Ezpeleta, Guillermo author Pozo Sanchez, Francisco author Ezpeleta, Carmen author Martínez-Baz, Iván author 2018 The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B. Euro Surveill. 2018 Feb;23(7). 10.2807/1560-7917.ES.2018.23.7.18-00057 1560-7917 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 29471624 http://hdl.handle.net/20.500.12105/8993 Case-control study Influenza Influenza vaccine Influenza-like illness Repeated vaccination Vaccine effectiveness Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18